Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34657
Abstract: The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE‐158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers.
read more here.
Keywords:
keynote 158;
158 study;
phase keynote;
pembrolizumab monotherapy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.01874
Abstract: PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067). We report efficacy…
read more here.
Keywords:
keynote 158;
endometrial cancer;
msi dmmr;
microsatellite instability ... See more keywords